ArticleInternal medicine journal2026
Feasibility and outcomes of kidney transplantation in patients with end-stage kidney disease after haemopoietic stem cell transplantation.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAdvances in haemopoietic stem cell transplantation (HSCT) have improved long-term survival, but they have also led to late complications, such as nephropathy. However, the safety and feasibility of kidney transplantation (KT) in patients with HSCT-related end-stage kidney disease (ESKD) remain unclear.
aimThis study aimed to evaluate the feasibility and clinical outcomes of KT in patients with ESKD following HSCT.
methodsThis study retrospectively analysed eight patients with ESKD who underwent KT following HSCT for haematologic disorders, including aplastic anaemia (n = 5), acute myeloid leukaemia (n = 2) and chronic myeloid leukaemia (n = 1).
resultsThe median time to progression to ESKD was 104 months after HSCT, with a median interval of 138 months between HSCT and KT. The causes of ESKD included diabetic nephropathy (n = 1), hypertensive nephropathy (n = 1), focal segmental glomerulosclerosis (n = 1), thrombotic microangiopathy (n = 1) and unknown aetiology (n = 4), with three diagnoses confirmed through kidney biopsy. Three patients received both HSCT and KT from the same donor, allowing them to completely discontinue immunosuppressive therapy. During a median follow-up of 55 months (range 2-143 months), there was only one case of acute T-cell-mediated rejection, and one patient died from sepsis due to a urinary tract infection. Notably, none of the patients experienced a recurrence of their original haematologic disease.
conclusionDespite concerns regarding immunosuppression and the risk of infection in this high-risk population, both patient and graft outcomes were favourable. These findings suggest that KT is a feasible and effective treatment option for patients with ESKD following HSCT, particularly when managed with personalised strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.